Adipothera uses an AI‑driven discovery platform that integrates biophysical modeling and multi‑modal omics data to design drug candidates that reprogram stromal cell responses toward durable tissue repair. Its pipeline includes locally delivered topical molecules for radiation injury and lymphedema, and an oral small‑molecule for fibrodysplasia ossificans progressiva/heterotopic ossification, each optimized for selective protein‑ligand activity, PK/PD alignment, and manufacturability.
Funding
Funding not disclosed
Founders
Product
Problem
Patients suffering from radiation‑induced tissue damage, chronic lymphedema, and heterotopic ossification have limited therapeutic options, often resulting in persistent inflammation, fibrosis, and abnormal bone formation that impair function and quality of life.
Solution
Adipothera applies AI‑driven discovery to program stromal cell responses, creating drug candidates that redirect the tissue microenvironment from pathological remodeling toward durable repair. By integrating multi‑modal biological data with biophysical modeling, the company designs molecules with selective protein‑ligand interactions that modulate stromal‑immune signaling. Lead candidates are optimized for local (topical) or systemic (oral) delivery, enabling targeted attenuation of inflammatory cascades while promoting structural recovery. Preclinical programs focus on radiation injury, lymphedema flares, and fibrodysplasia ossificans progressiva/heterotopic ossification, with readouts that differentiate repair from scarring. The platform aligns pharmacokinetic/pharmacodynamic modeling to clinical endpoints, supporting translational development of first‑in‑class therapies.
Target Audience
Primary customers are pharmaceutical development partners and biotech firms seeking stromal‑targeted therapeutics, as well as clinicians treating patients with radiation‑induced fibrosis, chronic lymphedema, or heterotopic ossification.
Features
- AI‑powered discovery engine that combines biophysical simulations with multi‑modal omics data to predict stromal‑targeted activity
- Computationally guided protein‑ligand selectivity to bias potency and safety profiles
- Localized topical formulation (AT‑001) for radiation injury and lymphedema, optimized for barrier penetration and residence time
- Oral small‑molecule candidate (AT‑002) for FOP/HO with selective interference of pro‑osteogenic stromal cues
- Preclinical assays that quantify repair versus scarring outcomes and monitor stromal‑immune modulation
- Integrated PK/PD modeling aligned to disease‑specific clinical endpoints
- Manufacturability screening for scalable production and oral bioavailability